Factory Price 99.0% Albiglutide CAS No.: 782500-75-8 with Good Quality
Product Description
|
Product name :Albiglutide
CAS No. : 782500-75-8
EINECS : 203-405-2 Molecular formula : C148h223n39o46 Molecular weight : 3284.58792 Appearance :White powder
Solubility : DMSO: ≥20 mg/mL Sample:Available Certification:COA,MSDS,FDA,SDS, Delivery term:DHL,FEDEX,UPS,USPS,Air freight,Sea freight Stock:in stock Storage:Cool dry area |
Albiglutide (tradenames Eperzan and Tanzeum) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. The drug was invented by Human Genome Sciences and was developed in collaboration with GSK.
Albiglutide has a half-life of four to seven days, which is considerably longer than the other two GLP-1 analogs approved for market use, exenatide (Byetta) and liraglutide (Victoza). GLP-1 drugs are currently only available for subcutaneous administration on a daily basis, so a GLP-1 drug with a longer half-life is desirable. Such a drug would only need to be injected biweekly or weekly instead of daily, reducing the discomfort and inconvenience of GLP-1 administration considerably. (NOTE that this information is out of date: exenatide is available as a weekly injection under the trade name Bydureon, which received FDA approval in January, 2012.); It has not yet been determined whether albiglutide is as effective an antidiabetic agent as GLP-1 drugs currently on the market, and final data remains to be published regarding the incidence of adverse effects related to the drug. To evaluate the efficacy and safety of the drug, albiglutide is undergoing eight Phase III clinical trials. Four of these trials should report useful data by end 2010.[needs update]6 GSK filed for FDA approval on 01/14/2013 and European Medical Agency (EMA) on 03/07/2013. On 08/02/2013 GSK released a press release pushing the marketing date 3 months to 04/15/2014.
In March 2014, GlaxoSmithKline PLC received approval from the European Commission to market albiglutide under the name 'Eperzan'.In April 2014, the FDA approved albiglutide under the name Tanzeum.
Our Advantages
1. Best quality with competitive price.
2. Quick shipping,delivery on time.
3. Alibaba Trade Assurances.
4. Support multiple trading methodsand payment.We support wire transfer, western union, Paypal or escrow (Alibaba) payment.
5. One to one business communication
6. OEM/ODM Avaliable.
7. We offer convenient one-station purchasing service.Our professionaland thoughtful after-sales service eliminates your worries.
8. We has manyyears' exporting experience in active pharmaceutical ingredient products.,Strictly on selecting raw materials.
Company Profile